MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Third Opinion Trial Synopsis:
This study is looking at a new treatment for people with multiple myeloma who have already received some treatments before. They want to see if a new medication called elranatamab, alone or with another medication called daratumumab, can be better than the current treatment that includes pomalidomide and dexamethasone. Part 1 of the study will test the safety and effectiveness of different doses of elranatamab and daratumumab together. Part 2 will randomly assign people to get elranatamab alone, elranatamab with daratumumab, or the current treatment. They will compare if elranatamab alone or with daratumumab works better than the current treatment. Part 3 will test a different dosing schedule for elranatamab and daratumumab. People will get treated until their disease gets worse, they have side effects, or they don't want to continue.

*Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment including lenalidomide and a proteasome inhibitor will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will compare the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab compared to daratumumab, pomalidomide, and dexamethasone. Participants in all parts of the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?

Contacts: